Question 1

What is Gumokimab?

Accepted Answer

Gumokimab is a Other.

Question 2

How often does Gumokimab appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was Gumokimab first tracked by Ergen?

Accepted Answer

First tracked on Jun 12, 2026.

Question 4

When was Gumokimab last mentioned in news?

Accepted Answer

Last active on Jun 12, 2026.

Question 5

What is Gumokimab's current news sentiment?

Accepted Answer

Aggregate sentiment score: 75 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Gumokimab in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Gumokimab?

Accepted Answer

Akeso's gumokimab approved in China (Jun 12, 2026, 7 articles).

Question 8

How did the "Akeso's gumokimab approved in China" event impact Gumokimab?

Accepted Answer

Gumokimab, an anti-IL-17 monoclonal antibody developed by Akeso, received NMPA approval for moderate-to-severe plaque psoriasis, demonstrating rapid and robust efficacy, durable skin clearance, and a favorable safety profile.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.